Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (June 2021)
12 slides from Noxopharm's investor presentation, June 2021
Slide 1: Delivering Science. Transforming Lives
Delivering Science. Transforming Lives NOXOPHARM CORPORATE PRESENTATION JUNE 2021 Discover Dr Graham Kelly Develop CEO and Managing Director NOXOPHARM LIMITED (ASX:NOX) Deliver NOXOPHARM LIMITED 1 PRESENTATION: JUNE 2021
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Noxopharm Limited (NOX or the Company). It Although the Company believes that the expectations reflected in the forward looking should not be considered as an offer or invitation to subscribe for, or purchase any statements included in this presentat
Slide 3: What Distinguishes Noxopharm (ASX:NOX)
WHAT DISTINGUISHES NOXOPHARM (ASX:NOX) A technology platform offering multiple opportunities – not isolated high-risk drug opportunities A platform offering a revolutionary concept in therapeutics A platform offering outcomes highly sought in the industry A platform we own outright – no licence fees
Slide 4: Four R&D Businesses in One Company
FOUR R&D BUSINESSES IN ONE COMPANY Veyonda® Cancer Research Veyonda® Pipeline Chronic inflammatory Cancer treatment Cancer growth Septic shock diseases/autoimmune enhancement factor inhibitors diseases NOXOPHARM LIMITED 4 PRESENTATION: JUNE 2021
Slide 5: 1. Veyonda - Cancer Treatment Enhancement
1. VEYONDA® - CANCER TREATMENT ENHANCEMENT IONIC - checkpoint inhibitor therapy DARRT - radiotherapy A revolutionary concept in cancer therapy involving a Programs drug (Veyonda®) with multiple mechanisms of action that CEP - chemotherapy boosts the effectiveness of other standard anti-cancer therap
Slide 6: 2. Cancer Research Pipeline - Cancer Growth Factor Inhibitors
2. CANCER RESEARCH PIPELINE - CANCER GROWTH FACTOR INHIBITORS Brain cancer (GBM) Programs Many cancers, particularly the Pancreatic cancer highly aggressive cancers, co- opt supporting healthy cells to supply growth factors that drive cancer cell growth. NOX has identified a novel family of drugs wi
Slide 7: 3. Veyonda - Septic Shock
3. VEYONDA® - SEPTIC SHOCK Inhibition of cytokine release syndrome Programs COVID-19 Cytokine release syndrome (CRS) is an inappropriately excessive immune response to viral and bacterial infections Sepsis generally Abnormal activation of STING signalling (response to tissue damage) thought to have
Slide 8: 4. Pharmorage - Chronic Inflammatory Diseases/Autoimmune Diseases
4. PHARMORAGE - CHRONIC INFLAMMATORY DISEASES/ AUTOIMMUNE DISEASES Chronic inflammation Pharmorage, a collaboration Programs between NOX and Hudson Institute of Medical Research, has identified a new family of Autoimmunity drug compounds with highly selective activity against STING Inappropriate STI
Slide 9: Our Management
OUR MANAGEMENT Dr Graham Kelly BSc(Vet), BVSc, PhD Shawn van Boheemen BBus, MCom, Chief Executive Officer FCPA, JP Chief Financial Officer photo Extensive experience in the biotechnology sector. Founder of four public companies: Noxopharm Senior finance executive having held finance (ASX:NOX), Novog
Slide 10: Key Metrics (at June 2021)
KEY METRICS (at 23 June 2021) News Flow (next 6 months) Market cap A$195m IONIC-1, DARRT-2 & CEP-2 start patient recruitment Share price A$0.68c COVID-19 clinical trial completion Novel drug pipeline progress Issued shares ~288.2m Pharmorage progressing novel drug development for chronic inflammatio
Slide 11: Our Value Proposition
OUR VALUE PROPOSITION What drug development companies rarely tell you We are significantly de-risked Not limited to a Multiple shots on single therapeutic goal field Aim is to assist existing therapies, Areas of major not rely on the test medical need and drug carrying the full industry interest Onl
Slide 12: For Further Information
FOR FURTHER INFORMATION: [email protected] Discover www.noxopharm.com Develop @Noxopharm Deliver NOXOPHARM LIMITED 12 PRESENTATION: JUNE 2021